Certara, a Princeton, N.J.-based global technology-enabled drug development and drug safety consultancy, has launched version 1.4 of its Phoenix product family.
Phoenix is a PK/PD software platform used by more than 5,000 biopharmaceutical companies, veterinary and academic researchers, and U.S., European, Japanese and other pharmaceutical regulatory agencies to analyze, manage, report and validate preclinical and clinical PK, PD and toxicokinetic (TK) data.
“Our clients choose the Phoenix platform because it allows them to optimize the most crucial drug development decisions in order to bring breakthrough drugs to patients,” said Edmundo Muniz, M.D., Ph.D., Certara CEO. “Our platform supports the concepts set forth in the Critical Path Initiative, an FDA program focused on the development of tools to streamline drug development. In order to meet global regulatory goals, we regularly update our Phoenix tools to maximize efficiencies and ensure that they continue to meet our customers’ evolving needs.”
Upgrades in Phoenix 1.4 include: